HBx Facilitates Drug Resistance in Hepatocellular Carcinoma via CD133-regulated Self-renewal of Liver Cancer Stem Cells (IMAGE)
Caption
This study found that HBV increases sorafenib and regorafenib resistance in HCCs through upregulation of CD133 and activation of the SRC/STAT3 signaling pathway. Our data provide a potentially key molecular target for drug resistance in HBV-infected HCCs, offering a strong theoretical basis for the development of specific and efficient treatments for HBV-infected HCCs.
Credit
Kuanhui Xiang, Xiangshu Jin
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC